HARBOUR BIOMED Revenue and Competitors
Estimated Revenue & Valuation
- HARBOUR BIOMED's estimated annual revenue is currently $10.2M per year.
- HARBOUR BIOMED received $85.0M in venture funding in August 2018.
- HARBOUR BIOMED's estimated revenue per employee is $77,500
- HARBOUR BIOMED's total funding is $312.8M.
Employee Data
- HARBOUR BIOMED has 131 Employees.
- HARBOUR BIOMED grew their employee count by -2% last year.
HARBOUR BIOMED's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, Chairman and CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | CTO | Reveal Email/Phone |
4 | Head Discovery Biology | Reveal Email/Phone |
5 | Senior Director | Reveal Email/Phone |
HARBOUR BIOMED Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $10.2M | 131 | -2% | $312.8M | N/A |
#2 | $4.2M | 54 | N/A | N/A | N/A |
#3 | $2.2M | 57 | -28% | $179.7M | N/A |
#4 | $23.9M | 309 | -14% | N/A | N/A |
#5 | $0.9M | 12 | 0% | N/A | N/A |
#6 | $1.7M | 22 | 0% | N/A | N/A |
#7 | $19M | 245 | -14% | N/A | N/A |
#8 | $9.4M | 121 | 3% | N/A | N/A |
What Is HARBOUR BIOMED?
Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery. The company is building its proprietary pipeline internally, through collaborations with co-development partners, and selective preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. Learn more about Harbour Biomed: www.harbourbiomed.com/
keywords:N/A
$312.8M
Total Funding
131
Number of Employees
$10.2M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
HARBOUR BIOMED News
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company";...
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel...
and ROTTERDAM, Netherlands and SUZHOU, China, March 24, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global...
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) applications for HBM4003, a next-generation ...
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) applications for HBM4003, a next-generation, ...
HARBOUR BIOMED Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-01-23 | $Undisclosed | A+ | CDH Investments | Article |
| 2018-08-27 | $85.0M | B | GIC Private Limited, | Article |